Orion receives positive CHMP opinion for new intensive care sedative, dexdor® (dexmedetomidine)
Orion Corporation has received information that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of marketing authorisation for dexdor® (dexmedetomidine), a new intensive care sedative.
The European Commission is expected to make the final decision on marketing authorisation in the coming months. If approved by the European Commission Orion would receive marketing authorisation for dexdor® in all European Union Member States.
Orion submitted a marketing authorisation application for dexmedetomidine for the evaluation by the European Medicines Agency in October 2010.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.